. v. Vaccine Response
'n Guinea?Bissau Children

- KJ, Nielsen F, Budtz-Jorgensen E, Benn C5, Grandjean P, Fisker AB

   
  
   
   
 
  
   
   
    
  
   
 
 
   
 

SE i?

au, West Africa.
Childre - ?1 olled in a randomised trial 

 
 

Half receiv-..? a measles ?a'ccination (MV) at
an.?
inclusion (4.5 'rsgonths) and 9 months of age. The

9 other half receiyed a at 9 months only.

RESULTS

     

Median

ETH 0 DS PFASS (ng/mL) (25_75 percentile)

?1

(n=237) 0.10 (0.09-0.14)

 

 
 

. PFOS (n=237) 0.77 (0.53-1.02)
Measles antibody levels were assessed at inclusion, PFOA (n=237) 0.68 (0.53?0.92)
. . . PFNA (n=236) 0.21 (0.13-0.31)
i) ?309th? and 2 years' PFDA (n=237) 0.19 (0.15?0.25)
were quantified in serum at inclusion.
9 
-: - . Differences in measles antibody concentration
oeiations between log(PFAS)s and log(measles

. with at doubling of serum-PFAS concentrations


odies at 9m int rvention rou . .
)1 age 0 p) 9 months (Intervention group)
rg-w. . -ge 2:years (control group) were examined

.5 .
?ea r-gressnon modelsdJusted for Pre vaccmation 

1914? since vaccination, sex, duration of

.1 
breas - :J?au?guand maternal education. Highly

.3 inleti ?1


  

PFNA (n=114) 
217233;: t?wefe excluded.



   

PFDA (n=115) 
., .

 

 

2 years (control group)

(fl-85) 

.. Fromm)

       
    
 

 


3
WWASS are unot'oxic for infants 
3"
ve -mo?gentratio ?1 


 

 


v.
v?

A. 

BAND 7' This work was supported by the Danish Health Foundation (Helsefonden) SDU 

 
 

a